Merck KGaA (FRA:MRK) received a €115.00 ($135.29) price target from analysts at Warburg Research in a note issued to investors on Thursday, November 9th. The firm presently has a “buy” rating on the healthcare company’s stock. Warburg Research’s price objective suggests a potential upside of 27.13% from the stock’s current price.
Several other equities analysts have also recently commented on MRK. J P Morgan Chase & Co set a €100.00 ($117.65) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, September 29th. Oddo Bhf set a €125.00 ($147.06) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Friday, September 29th. Deutsche Bank AG set a €106.00 ($124.71) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 4th. Kepler Capital Markets set a €115.00 ($135.29) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Monday, November 6th. Finally, Commerzbank Ag set a €109.00 ($128.24) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Wednesday, August 9th. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of €108.76 ($127.96).
Merck KGaA (FRA MRK) traded up €0.22 ($0.26) during trading hours on Thursday, hitting €90.46 ($106.42). The company had a trading volume of 254,903 shares. Merck KGaA has a 12 month low of €89.21 ($104.95) and a 12 month high of €115.00 ($135.29).
COPYRIGHT VIOLATION WARNING: This piece was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/21/warburg-research-analysts-give-merck-kgaa-mrk-a-115-00-price-target.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.